Cardiovascular Outcomes After Tixagevimab and Cilgavimab use for Pre-Exposure Prophylaxis Against Coronavirus Disease 2019: A Population-Based Propensity-matched Cohort Study

Abstract Tixagevimab and cilgavimab treatment was associated with higher rates of cardiovascular events in a post hoc analysis of a phase 3 trial. In this large population-based propensity-matched study, we found no increased risk of cardiovascular events up to 90 days after tixagevimab and cilgavim...

Full description

Saved in:
Bibliographic Details
Published inClinical infectious diseases Vol. 76; no. 8; pp. 1500 - 1503
Main Authors Birabaharan, Morgan, Hill, Eddie, Begur, Maedha, Kaelber, David C, Martin, Thomas C S, Mehta, Sanjay R
Format Journal Article
LanguageEnglish
Published US Oxford University Press 17.04.2023
Subjects
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - prevention & control
Cohort Studies
COVID-19 - prevention & control
Humans
Pre-Exposure Prophylaxis
cilgavimab
cardiovascular
COVID 19
evusheld
tixagevimab
Online AccessGet full text
ISSN1058-4838
1537-6591
1537-6591
DOI10.1093/cid/ciac894

Cover

Abstract Abstract Tixagevimab and cilgavimab treatment was associated with higher rates of cardiovascular events in a post hoc analysis of a phase 3 trial. In this large population-based propensity-matched study, we found no increased risk of cardiovascular events up to 90 days after tixagevimab and cilgavimab administration, including in patients with pre-existing cardiovascular disease.
AbstractList Tixagevimab and cilgavimab treatment was associated with higher rates of cardiovascular events in a post hoc analysis of a phase 3 trial. In this large population-based propensity-matched study, we found no increased risk of cardiovascular events up to 90 days after tixagevimab and cilgavimab administration, including in patients with pre-existing cardiovascular disease.
Abstract Tixagevimab and cilgavimab treatment was associated with higher rates of cardiovascular events in a post hoc analysis of a phase 3 trial. In this large population-based propensity-matched study, we found no increased risk of cardiovascular events up to 90 days after tixagevimab and cilgavimab administration, including in patients with pre-existing cardiovascular disease.
Tixagevimab and cilgavimab treatment was associated with higher rates of cardiovascular events in a post hoc analysis of a phase 3 trial. In this large population-based propensity-matched study, we found no increased risk of cardiovascular events up to 90 days after tixagevimab and cilgavimab administration, including in patients with pre-existing cardiovascular disease.Tixagevimab and cilgavimab treatment was associated with higher rates of cardiovascular events in a post hoc analysis of a phase 3 trial. In this large population-based propensity-matched study, we found no increased risk of cardiovascular events up to 90 days after tixagevimab and cilgavimab administration, including in patients with pre-existing cardiovascular disease.
Author Mehta, Sanjay R
Begur, Maedha
Hill, Eddie
Kaelber, David C
Martin, Thomas C S
Birabaharan, Morgan
Author_xml – sequence: 1
  givenname: Morgan
  surname: Birabaharan
  fullname: Birabaharan, Morgan
  email: mbirabaharan39@gmail.com
– sequence: 2
  givenname: Eddie
  surname: Hill
  fullname: Hill, Eddie
– sequence: 3
  givenname: Maedha
  surname: Begur
  fullname: Begur, Maedha
– sequence: 4
  givenname: David C
  surname: Kaelber
  fullname: Kaelber, David C
– sequence: 5
  givenname: Thomas C S
  surname: Martin
  fullname: Martin, Thomas C S
– sequence: 6
  givenname: Sanjay R
  surname: Mehta
  fullname: Mehta, Sanjay R
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36380460$$D View this record in MEDLINE/PubMed
BookMark eNp9kctrFTEYxYO02Ieu3EtWIsjUZJJ5ubsdqxYKLVjXQx5f7o3MTMY8yr3_lH-jsffqQrCLkHwfv3MC55yho9nNgNArSi4o6dh7ZXU-QrUdf4ZOacWaoq46epTfpGoL3rL2BJ2F8J0QSltSPUcnrGYt4TU5RT974bV1DyKoNAqPb1NUboKAVyaCx_d2K9bwYCchsZg17u24FvsxBcDGeXznobjaLi4kD3lwy2Y3iq3NDmth5xBx77ybs8ingD_aACILS0K7D3iF79ySv43WzcVl3utHA5iDjbtiElFt8qp3G-cj_hqT3r1Ax0aMAV4e7nP07dPVff-luLn9fN2vbgpVNiUvmo4BAeCqlsboBirZGSF1zWQra1mpSmhBpCw7Xpas5aajkioqgZfaaCUrdo7e7n0X734kCHGYbFAwjmIGl8JQNqyhtOF1ndHXBzTJCfSw-ByP3w1_Ms7Auz2gvAvBg_mLUDL8bnDIDQ6HBjNN_6GVjY8JRS_s-B_Nm73GpeVJ81_SWrF1
CitedBy_id crossref_primary_10_7759_cureus_41297
crossref_primary_10_1111_tid_14040
crossref_primary_10_1093_cid_ciad089
crossref_primary_10_3390_diseases10040118
crossref_primary_10_1007_s40264_024_01450_4
crossref_primary_10_3390_v15010118
crossref_primary_10_1007_s12185_023_03663_2
crossref_primary_10_1016_j_jaip_2023_07_045
Cites_doi 10.1016/S2213-2600(22)00180-1
10.1038/s41591-022-01689-3
10.1016/S0140-6736(21)00896-5
10.1056/NEJMoa2116620
10.15585/mmwr.mm7127a3
10.1161/CIRCULATIONAHA.120.046941
ContentType Journal Article
Copyright The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2022
The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Copyright_xml – notice: The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2022
– notice: The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1093/cid/ciac894
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList CrossRef

MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1537-6591
EndPage 1503
ExternalDocumentID 36380460
10_1093_cid_ciac894
10.1093/cid/ciac894
Genre Clinical Trial, Phase III
Journal Article
GroupedDBID ---
..I
.2P
.GJ
.I3
.ZR
08P
0R~
1KJ
1TH
29B
2AX
2WC
36B
3O-
4.4
48X
53G
5GY
5RE
5VS
5WD
6.Y
6J9
70D
AABZA
AACGO
AACZT
AAJKP
AAJQQ
AAMVS
AANCE
AAOGV
AAPGJ
AAPNW
AAPQZ
AAPXW
AAQQT
AARHZ
AASNB
AAUAY
AAUQX
AAVAP
AAWDT
AAYOK
ABBHK
ABEUO
ABIXL
ABJNI
ABKDP
ABLJU
ABNHQ
ABNKS
ABOCM
ABPLY
ABPTD
ABQLI
ABQNK
ABSAR
ABSMQ
ABTLG
ABWST
ABXSQ
ABXVV
ABZBJ
ACFRR
ACGFO
ACGFS
ACMRT
ACPQN
ACPRK
ACUFI
ACUTJ
ACUTO
ACYHN
ACZBC
ADACV
ADBBV
ADEYI
ADGZP
ADHKW
ADHZD
ADIPN
ADJQC
ADOCK
ADQBN
ADRIX
ADRTK
ADULT
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEJOX
AEKPW
AEKSI
AEMDU
AENEX
AENZO
AEPUE
AETBJ
AEUPB
AEWNT
AEXZC
AFFNX
AFFZL
AFIYH
AFOFC
AFRAH
AFSHK
AFXAL
AFXEN
AFYAG
AGINJ
AGKEF
AGKRT
AGMDO
AGQXC
AGSYK
AGUTN
AHMBA
AHXPO
AI.
AIAGR
AIJHB
AJEEA
ALMA_UNASSIGNED_HOLDINGS
ALUQC
APIBT
APJGH
APWMN
AQDSO
AQKUS
AQVQM
ASPBG
ATGXG
AVNTJ
AVWKF
AXUDD
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BTRTY
BVRKM
BZKNY
C1A
C45
CDBKE
CS3
CZ4
DAKXR
DCCCD
DIK
DILTD
DOOOF
DU5
D~K
E3Z
EBS
EE~
EIHJH
EJD
EMOBN
ENERS
ESX
F5P
F9B
FECEO
FEDTE
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
H13
H5~
HAR
HQ3
HTVGU
HVGLF
HW0
HZ~
IOX
IPSME
J21
J5H
JAAYA
JBMMH
JENOY
JHFFW
JKQEH
JLS
JLXEF
JPM
JSG
JSODD
JST
KAQDR
KBUDW
KOP
KSI
KSN
L7B
M49
MBLQV
MHKGH
MJL
ML0
N4W
N9A
NGC
NOMLY
NOYVH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OCZFY
ODMLO
ODZKP
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
O~Y
P2P
P6G
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
QBD
RD5
ROX
ROZ
RUSNO
RW1
RXO
SA0
SJN
TCURE
TEORI
TJX
TMA
TR2
VH1
W8F
X7H
Y6R
YAYTL
YKOAZ
YXANX
ZGI
~91
~S-
AAYXX
ABDFA
ABEJV
ABGNP
ABPQP
ABVGC
ADNBA
AEMQT
AGORE
AHGBF
AHMMS
AJBYB
AJNCP
ALXQX
CITATION
JXSIZ
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c2724-793e0ee4c6bffd7e5b9fabd63b8b6b5c5ada0bb29422384f91b1c1be42dfdcb53
ISSN 1058-4838
1537-6591
IngestDate Fri Jul 11 11:26:50 EDT 2025
Wed Feb 19 02:23:36 EST 2025
Tue Jul 01 01:18:51 EDT 2025
Thu Apr 24 23:10:36 EDT 2025
Wed Aug 28 03:18:24 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords cilgavimab
cardiovascular
COVID 19
evusheld
tixagevimab
Language English
License This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)
https://academic.oup.com/pages/standard-publication-reuse-rights
The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c2724-793e0ee4c6bffd7e5b9fabd63b8b6b5c5ada0bb29422384f91b1c1be42dfdcb53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://academic.oup.com/cid/article-pdf/76/8/1500/50001342/ciac894.pdf
PMID 36380460
PQID 2737117466
PQPubID 23479
PageCount 4
ParticipantIDs proquest_miscellaneous_2737117466
pubmed_primary_36380460
crossref_primary_10_1093_cid_ciac894
crossref_citationtrail_10_1093_cid_ciac894
oup_primary_10_1093_cid_ciac894
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-04-17
PublicationDateYYYYMMDD 2023-04-17
PublicationDate_xml – month: 04
  year: 2023
  text: 2023-04-17
  day: 17
PublicationDecade 2020
PublicationPlace US
PublicationPlace_xml – name: US
– name: United States
PublicationTitle Clinical infectious diseases
PublicationTitleAlternate Clin Infect Dis
PublicationYear 2023
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
References Montgomery (2023041720292140700_) 2022; 10
Xie (2023041720292140700_) 2022; 28
Wiemken (2023041720292140700_)
Singson (2023041720292140700_) 2022; 71
Clerkin (2023041720292140700_) 2020; 141
2023041720292140700
Levin (2023041720292140700_) 2022; 386
Katsoularis (2023041720292140700_) 2021; 398
References_xml – volume: 10
  start-page: 985
  year: 2022
  ident: 2023041720292140700_
  article-title: Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(22)00180-1
– volume: 28
  start-page: 583
  year: 2022
  ident: 2023041720292140700_
  article-title: Long-term cardiovascular outcomes of COVID-19
  publication-title: Nat Med
  doi: 10.1038/s41591-022-01689-3
– volume: 398
  start-page: 599
  year: 2021
  ident: 2023041720292140700_
  article-title: Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)00896-5
– volume: 386
  start-page: 2188
  year: 2022
  ident: 2023041720292140700_
  article-title: Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of Covid-19
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2116620
– ident: 2023041720292140700_
– volume: 71
  start-page: 878
  year: 2022
  ident: 2023041720292140700_
  article-title: Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID-19—COVID-NET, 10 States, March 2020–February 2022
  publication-title: MMWR Morb Mortal Wkly Rep
  doi: 10.15585/mmwr.mm7127a3
– ident: 2023041720292140700_
  article-title: COVID-19 severity and risk of subsequent cardiovascular events
  publication-title: Clin Infect Dis
– volume: 141
  start-page: 1648
  year: 2020
  ident: 2023041720292140700_
  article-title: COVID-19 and cardiovascular disease
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.120.046941
SSID ssj0011805
Score 2.4656384
Snippet Abstract Tixagevimab and cilgavimab treatment was associated with higher rates of cardiovascular events in a post hoc analysis of a phase 3 trial. In this...
Tixagevimab and cilgavimab treatment was associated with higher rates of cardiovascular events in a post hoc analysis of a phase 3 trial. In this large...
SourceID proquest
pubmed
crossref
oup
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1500
SubjectTerms Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - prevention & control
Cohort Studies
COVID-19 - prevention & control
Humans
Pre-Exposure Prophylaxis
Title Cardiovascular Outcomes After Tixagevimab and Cilgavimab use for Pre-Exposure Prophylaxis Against Coronavirus Disease 2019: A Population-Based Propensity-matched Cohort Study
URI https://www.ncbi.nlm.nih.gov/pubmed/36380460
https://www.proquest.com/docview/2737117466
Volume 76
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtNAEF2FIiFeEHfCdZF4ojL1_cJbCEGFqtCHVOpb5L24tVSSKImrwEfxUXwJZy927DZChRcrdry2kzmemd05M0PIG14k3OXCc9I4y53Q45mTu1HhhCmD-y5hgnUuzOHXeP84_HISnfR6v1uspWrF3vGfW_NK_keqOAa5qizZf5Bsc1EcwGfIF1tIGNtryXjYJZN-q1a4i1zuDnTj73G5hrK4KL_nTIcIhirMbnarpan1fbSQzmg9n6llQpUzgP_8PF-XuMJpXsJxhLpYwFW_KBfVUhXqVLGcXRjzzCS0HzXdv5wP-EanHcwVI371w4EnDDzgrrMzePiar9iJIA_rlMyaDoY72GhRa-VeMQ5USWnDONYtqDaL5SZiMhKi3FAD5Gm1MDlIUpw1Jucg17W8GhK_XRu2qx1-oAI3JrnTKmg30gugRmfLWmknThyZrl-1VjddZSx605aKhgfstsw9doOtpsSU2eIaOnhNeGqaMXdLdl8ypQ3B0YT2g4nqi2wH3yA3fUxllPH4-PmgiXR5qabZNr_L5pBi8B4G79nBHa-pk4l5ZUKkHaPxXXLHzmjowMDzHunJ6X1y69ByNh6QX12U0hqlVKOUtlBKgVK6QSkFSilQStsopS2UUotS2kIptSilCqXv6YBexii9ilFqMEo1Rh-S40-j8XDfsV1CHO4nfujAwEhXypDHrChEIiOWFTkTccBSFrOIR7nIXcb8LIQnnIZF5jGPe0yGvigEZ1HwiOxMZ1P5hNCIy5inflpAJiG8gCzkGAonthCu8JnfJ29rKUCqhiqjOrmcT7bIuw9FWJ88N5Vjtp_2CuL8-xmva1FPoPtVQC-fSryVE0w9Es9Lwjjuk8cGA82FAhhWRXp4er3HeEZub16352RntajkC7jbK_ZS4_UPZnTgKw
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cardiovascular+Outcomes+After+Tixagevimab+and+Cilgavimab+use+for+Pre-Exposure+Prophylaxis+Against+Coronavirus+Disease+2019%3A+A+Population-Based+Propensity-matched+Cohort+Study&rft.jtitle=Clinical+infectious+diseases&rft.au=Birabaharan%2C+Morgan&rft.au=Hill%2C+Eddie&rft.au=Begur%2C+Maedha&rft.au=Kaelber%2C+David+C&rft.date=2023-04-17&rft.issn=1058-4838&rft.eissn=1537-6591&rft.volume=76&rft.issue=8&rft.spage=1500&rft.epage=1503&rft_id=info:doi/10.1093%2Fcid%2Fciac894&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_cid_ciac894
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1058-4838&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1058-4838&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1058-4838&client=summon